Hepatocellular Carcinoma — Proceedings From a Session Held in Conjunction with the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI)

Featuring perspectives from Dr Anthony El-Khoueiry, Dr Richard S Finn, Dr Aiwu Ruth He and Dr Stacey Stein, moderated by Dr Stephen “Fred” Divers, including the following topics: Adjuvant Systemic Therapy for Early-Stage Hepatocellular Carcinoma (HCC) — Dr El-Khoueiry Introduction (0:00) Faculty Presentation (3:08) IMbrave050: Adjuvant systemic treatment for high-risk resected HCC — Robin K (Katie) Kelley, MD and Thomas A Abrams, MD (13:43) Neoadjuvant systemic therapy for patients with borderline resectable HCC — Dr Abrams (20:15) Case: A man in his early 70s with locally advanced HCC and tumor thrombus that extends into the right atrium — Ghassan Abou-Alfa, MD, MBA (24:34) Recent Developments in the Management of Intermediate-Stage HCC — Dr Finn  Faculty Presentation (31:18) EMERALD-1 and LEAP-012 trials of TACE with immunotherapy — Drs Abrams and Kelley (42:15) Systemic treatment for patients with Child-Pugh B cirrhosis and HCC — Dr Kelley (48:29) Use of immunotherapy for patients with autoimmune disorders: A man in his early 30s with active colitis and metastatic HCC receives first-line lenvatinib — Drs Abrams and Abou-Alfa (53:05) Current First-Line Therapy for Advanced HCC — Dr He Faculty Presentation (1:00:39) Selection of first-line treatment regimen for advanced HCC — Drs Abrams, Kelley and Abou-Alfa (1:12:00) Role of single-agent immunotherapy in the treatment of advanced HCC — Dr Kelley (1:18:22) Management of HCC in patients with discordant tumor markers or mixed tumor histology — Dr Abrams (1:23:03) Promising Investigational Front-Line Strategies for Advanced HCC; Selection and Sequencing of Therapy for Relapsed/Refractory HCC — Dr Stein  Faculty Presentation (1:29:42) Choice of tyrosine kinase inhibitor as second-line systemic treatment for HCC; prevention, monitoring and mitigation of lenvatinib-associated side effects — Dr Kelley (1:42:59) Case: A man in his early 70s with metastatic HCC that has rapidly progressed on atezolizumab/bevacizumab — Dr Abou-Alfa (1:49:27) Supportive care measures to manage ascites in patients with HCC — Dr Abrams (1:55:20) CME information and select publications